Wellington Management Group LLP boosted its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 27.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 140,119 shares of the company's stock after purchasing an additional 29,787 shares during the period. Wellington Management Group LLP owned about 0.37% of iTeos Therapeutics worth $837,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in ITOS. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of iTeos Therapeutics in the fourth quarter valued at approximately $42,000. CWM LLC raised its position in iTeos Therapeutics by 428.7% in the 1st quarter. CWM LLC now owns 8,554 shares of the company's stock valued at $51,000 after purchasing an additional 6,936 shares during the last quarter. Forefront Analytics LLC acquired a new position in iTeos Therapeutics in the fourth quarter worth $85,000. Graham Capital Management L.P. bought a new stake in shares of iTeos Therapeutics during the fourth quarter worth $85,000. Finally, Exchange Traded Concepts LLC increased its stake in shares of iTeos Therapeutics by 25.1% in the first quarter. Exchange Traded Concepts LLC now owns 17,308 shares of the company's stock valued at $103,000 after buying an additional 3,468 shares in the last quarter. 97.16% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several research analysts recently issued reports on ITOS shares. HC Wainwright downgraded shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, May 14th. Wall Street Zen raised shares of iTeos Therapeutics to a "sell" rating in a research note on Saturday, August 30th. Piper Sandler cut shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 21st. Leerink Partners reissued a "market perform" rating and issued a $9.00 price target (down previously from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Finally, Raymond James Financial set a $12.00 price objective on iTeos Therapeutics in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $15.50.
Check Out Our Latest Research Report on iTeos Therapeutics
iTeos Therapeutics Price Performance
ITOS stock remained flat at $10.15 during midday trading on Friday. The stock has a fifty day moving average of $10.15 and a two-hundred day moving average of $8.52. iTeos Therapeutics, Inc. has a 12 month low of $4.80 and a 12 month high of $17.63. The stock has a market cap of $448.73 million, a PE ratio of -2.17 and a beta of 1.31.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.51) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.39). As a group, analysts forecast that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.
Insiders Place Their Bets
In other iTeos Therapeutics news, CEO Michel Detheux sold 43,883 shares of the firm's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $10.02, for a total transaction of $439,707.66. Following the transaction, the chief executive officer owned 153,903 shares in the company, valued at approximately $1,542,108.06. This trade represents a 22.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 96,165 shares of company stock valued at $964,096 over the last quarter. Corporate insiders own 14.20% of the company's stock.
iTeos Therapeutics Company Profile
(
Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Featured Articles
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
